BPC-157

Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is a partial sequence of a protein known as Body Protection Compound that has been isolated from human gastric juice. Since its discovery, BPC-157 has been the subject of numerous preclinical studies investigating its effects on tissue repair mechanisms, gastrointestinal function, and cytoprotection in animal models. Published literature spans over two decades of research conducted primarily in rodent models, with investigations covering musculoskeletal, gastrointestinal, neurological, and vascular systems. The compound has demonstrated stability in human gastric juice, which is unusual for peptides of this size, and does not require a carrier for activity in published experimental protocols.

For research use only · Not FDA/EMA approved · Not for human consumption

Mechanism of Action

Published research suggests BPC-157 interacts with the nitric oxide (NO) system, modulating both constitutive and inducible NO-synthase pathways. Studies have described effects on angiogenesis through upregulation of VEGF (vascular endothelial growth factor) and its receptor VEGFR2, as well as modulation of the FAK-paxillin pathway involved in cell migration and tissue remodeling. Additional literature describes interactions with the dopaminergic system, GABAergic pathways, and serotonergic receptors. The peptide has been reported in animal studies to influence growth hormone receptor expression and to interact with the opioid system. Its cytoprotective effects have been attributed in published research to stabilization of cellular defense mechanisms and modulation of inflammatory mediators including prostaglandins, interleukins, and tumor necrosis factor pathways.

For research use only · Not FDA/EMA approved · Not for human consumption

Key Research Areas

• Gastrointestinal mucosal integrity and cytoprotection in rodent models
• Tendon, ligament, and muscle healing in experimentally induced injuries
• Bone fracture repair and periosteal reactions in animal models
• Neuroprotective effects in models of traumatic brain injury
• Corneal and retinal tissue repair in preclinical studies
• Vascular integrity and NO-system modulation
• Liver and pancreatic tissue protection in toxicity models

For research use only · Not FDA/EMA approved · Not for human consumption

Published Studies (8 cited)

For research use only · Not FDA/EMA approved · Not for human consumption

Dosage in Published Research

In published preclinical studies, BPC-157 has been administered to rodent models at doses typically ranging from 10 μg/kg to 10 μg per animal, via intraperitoneal (i.p.), intragastric, subcutaneous, or local application routes. Specific dosing protocols vary significantly across published studies depending on the injury model and target tissue being investigated. No standardized dosing protocol exists for research applications. All dosing information is derived from published literature and is presented for reference purposes only.

For research use only · Not FDA/EMA approved · Not for human consumption

Storage & Handling

Store lyophilized powder at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 14 days. Protect from light, moisture, and repeated freeze-thaw cycles. Handle under sterile laboratory conditions using appropriate PPE.

For research use only · Not FDA/EMA approved · Not for human consumption

Safety Profile (Literature Only)

Published preclinical studies have reported no observed toxic effects in rodent models at the doses investigated. No LD50 has been established in published literature. Studies have described BPC-157 as well-tolerated in animal models across multiple administration routes. No human clinical trial data is available to establish a safety profile in humans. This compound is for laboratory research use only.

For research use only · Not FDA/EMA approved · Not for human consumption